This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Mixed Depression and Anxiety: Serotonin1A Receptors as a Common Pharmacologic Link

Stephen M. Stahl, M.D., Ph.D.

Published: May 1, 1997

Article Abstract

Although depressive and anxious symptoms frequently coexist, most studies tend to dichotomizeanxiety disorders from depression. Consequently, pharmacologic agents are designated as antidepressantsor anxiolytics. A number of developments are reversing this trend. One is changes inconceptualization of generalized anxiety disorder (GAD) and major depressive disorder to recognizethe frequent existence of simultaneous symptoms of anxiety and depression in patients with relatedaffective and anxiety disorders. A second is the increasing recognition that subsyndromal symptomsof anxiety and depression frequently exist that do not reach thresholds for GAD or depression but thatmay decompensate to overt anxiety disorder or depression. A third is the discovery of partial agonistsfor serotonin1A receptor subtypes that have promising efficacy in mixed depression and anxiety.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: Anxiety , Anxiolytics

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...